Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

BISPHOSPHONATES FOR THE TREATMENT OF CALCITRIOL-INDUCED HYPERCALCEMIA

Identifieur interne : 000269 ( Pmc/Corpus ); précédent : 000268; suivant : 000270

BISPHOSPHONATES FOR THE TREATMENT OF CALCITRIOL-INDUCED HYPERCALCEMIA

Auteurs : Roselyn Cristelle Isidro Mateo ; Ricardo Ortiz ; Harold Noah Rosen

Source :

RBID : PMC:6876953

Abstract

Objective:

Calcitriol excess is a less common cause of hypercalcemia than hyperparathyroidism. Hypercalcemia due to calcitriol excess is usually managed acutely with intravenous (IV) fluid administration and dietary calcium restriction. Steroids and ketoconazole are second-line agents. There is evidence supporting the role of bone resorption in the genesis of hypercalcemia in vitamin D intoxication and for a rapid response of hypercalcemia to treatment with bisphosphonates. We seek to demonstrate the utility of bisphosphonates in calcitriol-induced hypercalcemia (CIH).

Methods:

We present the case of a patient with recurrent CIH from a follicular lymphoma who achieved normalization and subsequent stabilization of serum calcium levels following bisphosphonate administration

Results:

A 77-year-old woman with a history of non-small cell lung cancer was admitted with dry mouth, polyuria, weight loss, and fatigue. She was found to have a calcium level of 14.7 mg/dL (normal range is 8.5 to 10.2 mg/dL), 25-hydroxyvitamin D of 47 ng/mL (normal range is 30 to 60 ng/mL), 1,25-dihydroxyvitamin D of 89 pg/mL (normal range is 18 to 72 pg/mL), and parathyroid hormone of 19 pg/mL (normal range is 15 to 65 pg/mL), which recurred despite treatment with IV fluids and strict low-calcium diet. She received 5 mg of IV zoledronic acid and normocalcemia was maintained thereafter, without any diagnosis-specific treatment for >3 months. Positron emission tomography with computed tomography eventually showed new innumerable foci of increased uptake in the skeleton and lymph node biopsy revealed grade 3A follicular lymphoma.

Conclusion:

The first choice for CIH is treating the underlying cause. Bisphosphonates are, however, useful until a diagnosis is made, as they may be safer than steroids and can provide rapid relief even with a single treatment with minimal side effects.


Url:
DOI: 10.4158/ACCR-2019-0101
PubMed: 31967061
PubMed Central: 6876953

Links to Exploration step

PMC:6876953

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">BISPHOSPHONATES FOR THE TREATMENT OF CALCITRIOL-INDUCED HYPERCALCEMIA</title>
<author>
<name sortKey="Mateo, Roselyn Cristelle Isidro" sort="Mateo, Roselyn Cristelle Isidro" uniqKey="Mateo R" first="Roselyn Cristelle Isidro" last="Mateo">Roselyn Cristelle Isidro Mateo</name>
</author>
<author>
<name sortKey="Ortiz, Ricardo" sort="Ortiz, Ricardo" uniqKey="Ortiz R" first="Ricardo" last="Ortiz">Ricardo Ortiz</name>
</author>
<author>
<name sortKey="Rosen, Harold Noah" sort="Rosen, Harold Noah" uniqKey="Rosen H" first="Harold Noah" last="Rosen">Harold Noah Rosen</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">31967061</idno>
<idno type="pmc">6876953</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876953</idno>
<idno type="RBID">PMC:6876953</idno>
<idno type="doi">10.4158/ACCR-2019-0101</idno>
<date when="2019">2019</date>
<idno type="wicri:Area/Pmc/Corpus">000269</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000269</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">BISPHOSPHONATES FOR THE TREATMENT OF CALCITRIOL-INDUCED HYPERCALCEMIA</title>
<author>
<name sortKey="Mateo, Roselyn Cristelle Isidro" sort="Mateo, Roselyn Cristelle Isidro" uniqKey="Mateo R" first="Roselyn Cristelle Isidro" last="Mateo">Roselyn Cristelle Isidro Mateo</name>
</author>
<author>
<name sortKey="Ortiz, Ricardo" sort="Ortiz, Ricardo" uniqKey="Ortiz R" first="Ricardo" last="Ortiz">Ricardo Ortiz</name>
</author>
<author>
<name sortKey="Rosen, Harold Noah" sort="Rosen, Harold Noah" uniqKey="Rosen H" first="Harold Noah" last="Rosen">Harold Noah Rosen</name>
</author>
</analytic>
<series>
<title level="j">AACE Clinical Case Reports</title>
<idno type="eISSN">2376-0605</idno>
<imprint>
<date when="2019">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<sec>
<title>Objective:</title>
<p>Calcitriol excess is a less common cause of hypercalcemia than hyperparathyroidism. Hypercalcemia due to calcitriol excess is usually managed acutely with intravenous (IV) fluid administration and dietary calcium restriction. Steroids and ketoconazole are second-line agents. There is evidence supporting the role of bone resorption in the genesis of hypercalcemia in vitamin D intoxication and for a rapid response of hypercalcemia to treatment with bisphosphonates. We seek to demonstrate the utility of bisphosphonates in calcitriol-induced hypercalcemia (CIH).</p>
</sec>
<sec>
<title>Methods:</title>
<p>We present the case of a patient with recurrent CIH from a follicular lymphoma who achieved normalization and subsequent stabilization of serum calcium levels following bisphosphonate administration</p>
</sec>
<sec>
<title>Results:</title>
<p>A 77-year-old woman with a history of non-small cell lung cancer was admitted with dry mouth, polyuria, weight loss, and fatigue. She was found to have a calcium level of 14.7 mg/dL (normal range is 8.5 to 10.2 mg/dL), 25-hydroxyvitamin D of 47 ng/mL (normal range is 30 to 60 ng/mL), 1,25-dihydroxyvitamin D of 89 pg/mL (normal range is 18 to 72 pg/mL), and parathyroid hormone of 19 pg/mL (normal range is 15 to 65 pg/mL), which recurred despite treatment with IV fluids and strict low-calcium diet. She received 5 mg of IV zoledronic acid and normocalcemia was maintained thereafter, without any diagnosis-specific treatment for >3 months. Positron emission tomography with computed tomography eventually showed new innumerable foci of increased uptake in the skeleton and lymph node biopsy revealed grade 3A follicular lymphoma.</p>
</sec>
<sec>
<title>Conclusion:</title>
<p>The first choice for CIH is treating the underlying cause. Bisphosphonates are, however, useful until a diagnosis is made, as they may be safer than steroids and can provide rapid relief even with a single treatment with minimal side effects.</p>
</sec>
</div>
</front>
</TEI>
<pmc article-type="case-report">
<pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">AACE Clin Case Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">AACE Clin Case Rep</journal-id>
<journal-id journal-id-type="publisher-id">cecr</journal-id>
<journal-id journal-id-type="pmc">AACE Clin Case Rep</journal-id>
<journal-title-group>
<journal-title>AACE Clinical Case Reports</journal-title>
</journal-title-group>
<issn pub-type="epub">2376-0605</issn>
<publisher>
<publisher-name>American Association of Clinical Endocrinologists</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31967061</article-id>
<article-id pub-id-type="pmc">6876953</article-id>
<article-id pub-id-type="doi">10.4158/ACCR-2019-0101</article-id>
<article-id pub-id-type="sici">i2376-0605-5-5-e316</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>BISPHOSPHONATES FOR THE TREATMENT OF CALCITRIOL-INDUCED HYPERCALCEMIA</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mateo</surname>
<given-names>Roselyn Cristelle Isidro</given-names>
</name>
<degrees>MD, MS</degrees>
<xref ref-type="author-notes" rid="fn1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ortiz</surname>
<given-names>Ricardo</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="author-notes" rid="fn1"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Rosen</surname>
<given-names>Harold Noah</given-names>
</name>
<degrees>MD, CCD</degrees>
<xref ref-type="author-notes" rid="fn1"></xref>
</contrib>
</contrib-group>
<author-notes>
<fn id="fn1">
<p>From the Department of Medicine, Division of Endocrinology and Metabolism, Beth Israel Deaconess Medical Center, Boston, Massachusetts.</p>
</fn>
<corresp id="cor1">Address correspondence to Dr. Harold Rosen, Division of Endocrinology, GZ-6, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. E-mail:
<email>hrosen@bidmc.harvard.edu</email>
.</corresp>
<fn fn-type="COI-statement">
<p>
<bold>DISCLOSURE</bold>
</p>
<p>The authors have no multiplicity of interest to disclose.</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<season>Sep-Oct</season>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>6</month>
<year>2019</year>
</pub-date>
<volume>5</volume>
<issue>5</issue>
<fpage>e316</fpage>
<lpage>e320</lpage>
<history>
<date date-type="received">
<day>22</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>6</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 AACE.</copyright-statement>
<copyright-year>2019</copyright-year>
</permissions>
<abstract>
<sec>
<title>Objective:</title>
<p>Calcitriol excess is a less common cause of hypercalcemia than hyperparathyroidism. Hypercalcemia due to calcitriol excess is usually managed acutely with intravenous (IV) fluid administration and dietary calcium restriction. Steroids and ketoconazole are second-line agents. There is evidence supporting the role of bone resorption in the genesis of hypercalcemia in vitamin D intoxication and for a rapid response of hypercalcemia to treatment with bisphosphonates. We seek to demonstrate the utility of bisphosphonates in calcitriol-induced hypercalcemia (CIH).</p>
</sec>
<sec>
<title>Methods:</title>
<p>We present the case of a patient with recurrent CIH from a follicular lymphoma who achieved normalization and subsequent stabilization of serum calcium levels following bisphosphonate administration</p>
</sec>
<sec>
<title>Results:</title>
<p>A 77-year-old woman with a history of non-small cell lung cancer was admitted with dry mouth, polyuria, weight loss, and fatigue. She was found to have a calcium level of 14.7 mg/dL (normal range is 8.5 to 10.2 mg/dL), 25-hydroxyvitamin D of 47 ng/mL (normal range is 30 to 60 ng/mL), 1,25-dihydroxyvitamin D of 89 pg/mL (normal range is 18 to 72 pg/mL), and parathyroid hormone of 19 pg/mL (normal range is 15 to 65 pg/mL), which recurred despite treatment with IV fluids and strict low-calcium diet. She received 5 mg of IV zoledronic acid and normocalcemia was maintained thereafter, without any diagnosis-specific treatment for >3 months. Positron emission tomography with computed tomography eventually showed new innumerable foci of increased uptake in the skeleton and lymph node biopsy revealed grade 3A follicular lymphoma.</p>
</sec>
<sec>
<title>Conclusion:</title>
<p>The first choice for CIH is treating the underlying cause. Bisphosphonates are, however, useful until a diagnosis is made, as they may be safer than steroids and can provide rapid relief even with a single treatment with minimal side effects.</p>
</sec>
</abstract>
<counts>
<page-count count="5"></page-count>
</counts>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000269 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000269 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:6876953
   |texte=   BISPHOSPHONATES FOR THE TREATMENT OF CALCITRIOL-INDUCED HYPERCALCEMIA
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:31967061" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021